Delivery Order 75N95023D00019-75N95025F00001
Award Date
5/2/25
Potential Completion Date
11/1/26
Potential Value
$1.3M
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Overland Park, KS 66212, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,562,513 cost-plus-fixed-fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc. The contract is for pharmacokinetic and pharmacodynamic studies to support the development of medications for substance use disorders. The contract period of performance is from September 20, 2017 to September 19, 2022, with an ultimate completion date of July 31, 2025. This award is not associated...
This federal contract award was made by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization specializing in early phase drug development services. The $1,293,840.24 firm fixed price definitive contract is for a project on the pharmacokinetics study of an opioid drug product following insufflation of milled drug products. The contract has an ultimate completion date of September 30, 2019 and was awarded on September 17, 2015. No...
The Food and Drug Administration (FDA) awarded a $2,370,057 firm fixed price definitive contract to Altasciences Clinical Kansas Inc., a contract research organization, for a dose-finding pilot study of kratom alkaloids to be conducted in Silver Spring, Maryland through September 2024. This award was not set aside under any small business programs. Altasciences has prior experience providing clinical pharmacology research services to federal agencies, including a $1.8 million firm fixed price...
This is a $983,066 firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization, to conduct a bioequivalence study of lamotrigine extended release tablets. The delivery order was issued against an existing $21 million single-award indefinite delivery contract with the National Institute on Drug Abuse (NIDA) for pharmacokinetic and pharmacodynamic trials to develop medications for substance use...
This is a $3,358,776 cost-plus-fixed-fee Delivery Order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO). The award is for a Phase I randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of a medical product. The contract is a task order under NIDA's "Phase I Clinical Trials for Development of Neurotherapeutics" Indefinite...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Southern Research Institute, a non-profit organization. The $1,593,565.26 contract is under the Pharmacology and Toxicology for Neurotherapeutics Program (PTNP) indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The contract is for the 28-day oral toxicity study in monkeys with a 33-day recovery period. Southern Research Institute has subcontracted a...
This is a $4,026,071.62 cost-plus-fixed-fee contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health, to SD Solutions LLC, an 8(a) small disadvantaged business based in Rockville, Maryland. The contract is for the NIDA Clinical Trials Research Coordination Center, which will provide logistical and operational support services for NIDA's National Drug Abuse Treatment Clinical Trials Network. This includes coordinating meetings,...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Pharmaron, Inc. for $149,520.00. The award is under the NIH Bioanalysis Testing Services 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract vehicle. Pharmaron, a minority-owned, for-profit contract research organization (CRO), will provide pharmacokinetics assessments, toxicity studies, and ion channel testing...
<p>The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $24,900 firm fixed price purchase order contract to Pelago Bioscience AB, a for-profit limited liability company. The contract is for the development of a new assay to test compounds of interest. The period of performance runs from the award date of September 9, 2024 through September 8, 2025. This contract award does not have a set-aside designation.</p>
This federal contract award was issued by the National Institute on Drug Abuse (NIDA), a civilian agency, to Sri International, a non-profit research and development institute. The contract, valued at $175,508.78, is for non-rodent pharmacokinetic assessment services under NIDA's Pharmacology and Toxicology for Neurotherapeutics Program (PTNP). The contract is a delivery order under the PTNP indefinite delivery vehicle (IDV) and has a cost-plus-fixed-fee pricing type. The contract does not...